Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?

MeSH terms

• Aminoglycosides* / administration & dosage
• Aminoglycosides* / therapeutic use
• Anti-Bacterial Agents* / administration & dosage
• Anti-Bacterial Agents* / therapeutic use
• Cerebral Ventriculitis* / drug therapy
• Cerebral Ventriculitis* / microbiology
• Drug Resistance, Multiple, Bacterial*
• Gram-Negative Bacteria / drug effects
• Gram-Negative Bacterial Infections* / drug therapy
• Gram-Negative Bacterial Infections* / microbiology
• Humans
• Injections, Spinal*
• Meningitis, Bacterial* / drug therapy
• Meningitis, Bacterial* / microbiology
• Polymyxins* / administration & dosage
• Polymyxins* / therapeutic use
• Treatment Outcome
• beta-Lactamase Inhibitors / administration & dosage
• beta-Lactamase Inhibitors / therapeutic use
• beta-Lactams / administration & dosage
• beta-Lactams / therapeutic use